UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2278-5
Program Prior Authorization/Medical Necessity
Medication Omnipod® 5, TwiistTM
P&T Approval Date 5/2022, 9/2022, 11/2023, 11/2024, 3/2025
Effective Date 6/1/2025
1. Background:
External insulin pumps are used for managing individuals with diabetes and deliver insulin by
continuous subcutaneous infusion. OmniPod 5 is indicated for management of type 1 diabetes
in persons aged 2 and older and in persons with type 2 diabetes aged 18 and older. Twiist is
indicated in persons aged 6 and older with type 1 diabetes. Members will be required to meet
the following coverage criteria.
2. Coverage Criteriaa:
A. Initial Authorization
1. Omnipod 5 or Twiist will be approved based on one of the following criteria:
a. All of the following:
(1) One of the following:
(a) For Omnipod 5: Diagnosis of diabetes
(b) For Twiist: Diagnosis of Type 1 diabetes
-AND-
(2) All of the followingb:
(a) Patient regularly tests blood glucose > 4 times/day or utilizes a continuous
glucose monitor (CGM) for > 8 weeks
(b) Patient has completed a diabetes management program
(c) Patient injects insulin > 3 times/day
-AND-
(3) Both of the following:
(a) Patient or caregiver is motivated to assume responsibility for self-care and
insulin management
(b) Patient or caregiver demonstrates knowledge of importance of nutrition
including carbohydrate counting and meal planning.
-OR-
© 2025 UnitedHealthcare Services, Inc.
1
b. For continuation of therapy
Authorization will be issued for 12 months.
B. Reauthorization
1. Omnipod 5 or Twiist will be approved for continuation of therapy based on the following
criteriab:
a. Documentation of positive clinical response
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
b In Florida, Maine, Tennessee, and Texas only, diabetes medications may be approved based on
both of the following: 1) Provider attests use of this product is medically necessary; and- 2) If
applicable, clinical characteristics exist that preclude the use of the covered preferred
alternative(s) and use of the covered preferred alternative(s) could result in worsening of
patient’s condition or inadequate treatment (document alternatives and clinical information
related to worsening/inadequate treatment).
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
• Coverage is not provided for indications unproven per medical benefit drug policy.
4. References:
1. American Diabetes Association. Diabetes Technology: Standards of Care in Diabetes - 2024.
Diabetes Care 2024; 47S126-S144.
2. Blonde L, Umpierrez G, Reddy S, et al.; American Association of Clinical Endocrinology
Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan- 2022
Update. Endocrine Practice 28(2022)923-1049.
Program Prior Authorization/Medical Necessity – Omnipod 5
Change Control
5/2022 New program.
9/2022 Added continuation of therapy. Clarified that CGM could be used to
monitor blood glucoses.
11/2023 Annual review. Updated references.
11/2024 Annual review. Updated references.
© 2025 UnitedHealthcare Services, Inc.
2
3/2025 Added Twiist to criteria. Removed requirement for hypoglycemia,
unpredictable blood glucose swings, or HbA1C outside of goal.
© 2025 UnitedHealthcare Services, Inc.
3